Table I.
Treatment group, % | |||||
---|---|---|---|---|---|
Cell cycle phase | A, Nimotuzumab | B, Cisplatin | C, Sequential treatment | D, Simultaneous treatment | E, Untreated control |
G0/G1 | 61.72±1.68 | 66.40±2.31 | 72.23±2.07 | 62.28±1.68 | 58.25±1.07 |
S | 12.32±1.32 | 8.78±0.91 | 5.87±0.78 | 11.01±1.37 | 15.35±0.54 |
G2-M | 24.91±0.62 | 24.48±2.80 | 24.16±1.86 | 26.71±1.31 | 26.40±0.53 |
Data are presented as the mean ± standard deviation.